Skip to main content
Fig. 2 | BMC Gastroenterology

Fig. 2

From: Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial

Fig. 2

Bile acid uptake and synthesis: (a) total faecal bile acid content on day 28 and change from baseline to day 28 in (b) total serum bile acid and (c) C4 concentration. n is the number of participants with available data on day 28. Data are from the pharmacodynamic analysis set. aDetermined over 48 h between days 26 and 28. C4 7α-hydroxy-4-cholesten-3-one; SD standard deviation; T2DM type 2 diabetes

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us